Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).
Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Herbst R, Kelly K. Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A). Journal Of Clinical Oncology 2021, 39: 9075-9075. DOI: 10.1200/jco.2021.39.15_suppl.9075.Peer-Reviewed Original ResearchVascular endothelial growth factorThromboembolic eventsAdvanced non-small cell lung cancerNon-small cell lung cancerPlatinum-based doublet therapyPD-L1 inhibitor therapyGrade 5 AEsTreatment-related AEsVEGF receptor inhibitionGrade 3 toxicityAdverse event profilePD-L1 expressionAdverse event assessmentCell lung cancerDuration of responseTumor immune microenvironmentStandard of carePhase IIEndothelial growth factorMultiple tumor typesCare armCommon AEsECOG 0Checkpoint inhibitorsDoublet therapy